Atezolizumab (atezo) with or without Bacille Calmette-Guerin (BCG) in patients (pts) with high-risk nonmuscle-invasive bladder cancer (NMIBC): Results from a phase Ib/II study. Hahn, N. M., Steinberg, G. D., Stratton, K., Kopp, R. P., Sankin, A., Skinner, E. C., Pohar, K. S., Gartrell, B., Pham, S., Rishipathak, D., Mariathasan, S., Davarpanah, N. N., Carter, C., Inman, B. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for DOI 10.1200/JCO.2022.40.6_suppl.493

View details for Web of Science ID 000771008900500